AIM ImmunoTech Inc. Stock News

OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company's belief that its d

AIM ImmunoTech Inc announced that it has finalized the protocol for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The company expec

Finalizes and reports Phase 2 study protocol

Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of

AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses. The HCT

AIM ImmunoTech Inc. said it has signed a signed clinical trial agreement for a Phase 2a Human Challenge Trial (HCT) with hVIVO for a Phase 2a Human Challenge Trial (HCT) to test the company's flagship

The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter The governin

AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two separate Phase 2 clinical studie

AIM ImmunoTech Inc announced it had submitted a pre-investigational New Drug application (pre-IND) to the US Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study Ampli

AIM Has Reached Multiple Major Milestones Demonstrating Strong Progress in Developing its COVID-19 Portfolio AIM Has Reached Multiple Major Milestones Demonstrating Strong Progress in Developing its C

AIM ImmunoTech Inc said it has submitted a provisional patent application for Ampligen as a potential early-onset intranasal therapy. This therapeutic use is designed to enhance and expand infection-i

OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset intranas

AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive Dysfunction (PCCD).  The meeting requ

AIM ImmunoTech Inc has progressed a step further in its bid to get Ampligen into a clinical trial to test it as an infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD) - a new and serious c

OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (